Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

To the Editor We read with interest the work by Duan and colleagues¹ and commend their remarkable contribution to the evidence base on immunotherapy. Although the use of anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) agents revolutionized cancer treatment, a direct comparison between the classes is still lacking. The authors suggest that anti–PD-1 is superior to anti–PD-L1, lowering the risk of death by 22% and 32% as monotherapy or in combination with standard therapies, respectively.